Hypertension, hypertrophy, heart failure

Heart

Volumn 76, Issue 3 SUPPL. 3, 1996, Pages 92-97

  Nicholls, M Gary ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0029987294     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.76.3_suppl_3.92     Document Type: Review

References (79)

1. Garg R, Packer M, Pitt B, Yusuf S. Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. J Am Coll Cardiol 1993;22:3 5A.
2. Eriksson H. Heart failure: a growing public health problem. J Intern Med 1995;237:135 41.
3. Marantz PR, Alderman MH, Tobin JN. Diagnostic heterogeneity in clinical trials for congestive heart failure. Ann Intern Med 1988;109:55 61.
4. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995;26:1565 74.
5. The Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J 1995;16:741 51.
6. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions (published erratum appears in N Engl J Med 1992;327:1768). N Engl J Med 1992;327:685 91.
7. Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation 1993;87:755 63.
8. McMurray J, Hart W, Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK. Br J Med J Economics 1993;6:99 110.
9. Launois B, Reboul-Marty J, Battais J, Lefebvre P. Le coût de la sévérité de la maladie: le cas de l'insuffisance-cardiaque. J d'Economic Médicale 1990:8;395 412.
10. Doughty R, Yee T, Sharpe N, MacMahon S. Hospital admissions and deaths due to congestive heart failure in New Zealand, 1988 91. N Z Med J 1995;108:473 5.
11. Clawson BJ. Incidence of types of heart disease among 30,265 autopsies, with special reference to age and sex. Am Heart J 1941;22:607 24.
12. Wartman WB, Hellerstein HK. The incidence of heart disease in 2,000 consecutive autopsies. Annals Int Med 1943;41 65.
13. Doyle AE Does hypertension predispose to coronary disease? Conflicting epidemiological and experimental evidence. Am J Hypertens 1988;1:319 24.
14. Bechgaard P. A 40 years' follow-up study of 1000 untreated hypertensive patients. Clin Sci Mol Med Suppl 1976;3:673 5S.
15. Perera GA. Hypertensive vascular disease: description and natural history. J Chon Dis 1955;1:55 42.
16. Smirk FH. Congestive heart failure. In: Smirk FH, ed. High arterial pressure. Oxford: Blackwell, 1957:86 8.
17. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med 1972;287:781 7.
18. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Call Cardiol 1993;22:6 13A.
19. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88: 107 15.
20. Sagie A, Larson MG, Levy D. The natural history of borderline isolated systolic hypertension. N Engl J Med 1993;329:1912 7.
21. Eriksson H, Svärdsudd K, Caidahl K, Bjurö T, Larsson B, Welin L, et al. Early heart failure in the population. The study of men born in 1913. Acta Med Scand 1988;223: 197 209.
22. Alexander M, Grumbach K, Selby J, Brown AF, Washington E. Hospitalization for congestive heart failure. Explaining racial differences. JAMA 1995;274: 1037 42.
23. Collins R, Peto R, MacMahon S, Hehert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827 38.
24. Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;i:1349 54.
25. Dahlöf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281 5.
26. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255 64.
27. Vogt M, Strauer BE. Systolic ventricular dysfunction and heart failure due to coronary microangiopathy in hypertensive heart disease. Am J Cardiol 1995;76:48 53D.
28. Kannel WB, Sorlie P, Castelli WP, McGree D. Blood pressure and survival after myocardial infarction: the Framingham study. Am J Cardiol 1980;45:326 30.
29. Andersson B, Waagstein F. Spectrum and outcome of congestive heart failure in a hospitalized population. Am Heart J 1993;126:632-40.
30. Rabkin SW, Mathewson FA, Tate RB. Prognosis after acute myocardial infarction: relation to blood pressure values before infarction in a prospective cardiovascular study. Am J Cardiol 1977;40:604 10
31. Kannel WB, Dannenberg AL, Abbott RD. Unrecognized myocardial infarction and hypertension: the Framingham study. Am Heart J 1985;109:581 5.
32. Sideris DA, Toumanidis ST, Kostis EB, Diakos A, Moulopoulos SD. Arrhythmogenic effect of high blood pressure: some observations on its mechanism. Cardiovasc Res 1989;23:983 92.
33. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982;306:1018 22.
34. Anderson KP. Sudden death, hypertension, and hypertrophy. J Cardiovasc Pharmacol 1984;6(suppl 3):S498 503.
35. Ghali JK, Kadakia S, Cooper RS, Liao YL. Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 1991;17:1277 82.
36. Lauer MS, Anderson KM, Levy D. Influence of contemporary versus 30-year blood pressure levels on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol 1991;18:1287 94.
37. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213:1143 52.
38. Effects of treatment on morbidity in hypertension. III. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation 1972;45:991-1004.
39. Hansson L. Does drug treatment improve survival in mildto-moderate hypertension? J Hypertens 1995;13:1354 5.
40. Zanchetti A. Antihypertensive therapy: pride and prejudice. J Hypertens 1995;13:1522 8.
41. Lew EA. High blood pressure, other risk factors and longevity: the insurance viewpoint. Am J Med 1973;55: 281 94.
42. Metropolitan Lite Insurance Company. Blood pressure: insurance experience and its implications. New York: Metropolitan Life Insurance Company, 1961.
43. Drizd T, Dannenberg AL, Engel A. Blood pressure levels in persons 18-74 years of age in 1976-1980, and trends in BP from 1960-1980 in the United States. In: Dept. Of Health and Human Services Vital and health statistics. Series 11, No 234. Washington, DC: Public Health Service, National Center for Health Statistics; 1986 July. Publication No: PHS-86-1684:1-68.
44. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States, 1973-1986. Evidence for increasing population prevalence. Arch Intern Med 1990;150:769-73.
45. Yusuf S, Thom T, Abbott RD. Changes in hypertension treatment and in congestive heart failure mortality in the United States. Hypertension 1989;13:174-9.
46. Kannel WB. Framingham study insights into hypertensive risk of cardiovascular disease. Hypertens Res 1995;18:181-96.
47. Lenfant C. Report of the Task Force on Research in Heart Failure [news]. Circulation 1994;90:1118-23.
48. Sever P, Beevers G, Bulpitt C, Lever A, Ramsay L, Reid J, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993;306:983-7.
49. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. 1993 guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Hypertension 1993;22:392-403.
50. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-83.
51. Guidelines for the Management of Mildly Raised Blood Pressure in New Zealand. Core Services Committee, PO Box 5013, Wellington, New Zealand.
52. Johannesson M. The cost effectiveness of hypertension treatment in Sweden. Pharmaco Economics 1995;7: 242-50.
53. Johannesson M. The cost-effectiveness of the switch towards more expensive antihypertensive drugs. Health Policy 1994;28:1-13.
54. Swales JD. The Harveian Oration of 1995. The growth of medical science: the lessons of Malthus. J R Coll Physicians Lond 1995;29:490-501.
55. World Hypertension League. Economics of hypertension control. Bull WHO1995;73:417-24.
56. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994;13:S107-12.
57. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl JMed 1996;334:13-8.
58. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, et al. The heart in hypertension (published erratum appears in N Engl J Med 1992;327: 1768). N Engl J Mcd 1992;327:998-1008.
59. Bikkina M, Larson MG, Levy D. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. J Am Coll Cardiol 1993;22:1111-6.
60. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
61. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donate F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995;13:1091-5.
62. Mensah GA, Pappas TW, Koren MJ, Ulin RJ, Laragh JH, Devereux RB, Comparison of classification of the severity of hypertension by blood pressure level and by World Health Organization criteria in the prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension. J Hypertens 1993;11:1429-40.
63. Devereux RB, Roman MJ. Hypertensive cardiac hypertrophy: pathophysiologic and clinical characteristics. In: Laragh JH and Brenner BM, eds. Hypertension, pathophysiology, diagnosis, and management. New York: Raven Press, 1995:409-32.
64. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995;96:1280-7.
65. Struthers AD. Prospects for using a blood sample in the diagnosis of heart failure. Q J Med 1995;88:303-6.
66. Motwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 1993;341:1109-13.
67. Diez J, Laviades C, Monreal I, Gil MJ, Panizo A, Pardo J. Toward the biochemical assessment of myocardial fibrosis in hypertensive patients. Am J Cardiol 1995;76:14-17D.
68. Weber KT, Brilla CG, Cleland JG, Cohn JN, Hansson L, Heagerty AM, et al. Cardioreparation and the concept of modulating cardiovascular structure and function. Blood Pressure 1993;2:6-21.
69. Raman VK, Lee YA, Lindpaintner K. The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. Am J Cardiol 1995;76:18-23D.
70. Westerhof N, O'Rourke MF. Haemodynamic basis for the development of left ventricular failure in systolic hypertension and for its logical therapy. J Hypertens 1995; 13:943-52.
71. Schachter M. Drug-induced modification of vascular structure: effects of antihypertensive drugs. Am Heart J 1991; 122:316-23.
72. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995;25:474-81.
73. Van Bortel LM, Kool MJ, Spek JJ. Disparate effects of antihypertensive drugs on large artery distensibility and compliance in hypertension. Am J Cardiol 1995;76:46-9E.
74. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
75. Richards AM, Nicholls MG, Crozier IG. Role of ACE inhibitors in hypertension with left ventricular hypertrophy. Br Heart J 1994;72:S24-32.
76. Agabiti-Rosei E, Ambrosioni E, Palù CD, Muiesan ML, Zanchetti A. ACE inhibitor ramipril is more effective than the β-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study. J Hypertens 1995;13: 1325-34.
77. Liebson PR, Grandits GA, Dianzumba S, Prineas RJ, Grimm RH, Neaton JD, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995;91:698-706.
78. Devereux RB, Dahlöf B. Criteria for an informative trial of left ventricular hypertrophy regression. J Human Hypertens 1994;8:735-9.
79. Kostis JB. The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Am J Hypertens 1995;8:909-14.